Smart AI Quantification for Precision Medicine
We innovate pathology with AI-powered biomarker quantification in precision medicine. Our technology enables fast and accurate patient screening for targeted cancer therapy, thus improving patient outcomes worldwide.
What makes AIVIS special?
Practical Solution
MFDS-certified for clinical use—fast, accurate, and seamlessly integrated with an intuitive UI/UX for maximum efficiency
Robustness
Extensive internal and extensive validation across diverse staining protocols and scanners with leading hospitals
Pathologist-Friendly
Developed with in-house, full-time pathologists who annotate at the cellular level, ensuring unmatched accuracy and deep clinical relevance
Patient Privacy & Data Security
Advanced security and anonymization protocols safeguard patient data with the highest standards
Pioneering Precision Medicine through AI
Our Milestones
2024
2023
2022
2021
Obtention of the Medical Device Quality Management System Certificate (ISO 13485:2016)
Obtention of the Korea Good Manufacturing Practices of In-Vitro Diagnostic Device (KGMP)
Launch of "PathoAiD®-Qanti IHC" - A solution for Quantifying Companion Diagnostic Biomarkers ER, PR, HER2, and Ki-67 based on IHC-stained histopathology images
Launch of "PathoAiD®-Thyroid Dx" - A precision Pathology Diagnostic solution for thyroid nodules based on Core Needle Biopsy (CNB)
Launch of "PathoAiD®-Colon Dx" - A precision Pathology Diagnostic solution for colorectal polyps
Our Leadership
Chief Executive Officer
Daehong Lee
Ph.D.
Daehong Lee is a distinguished leader in the field of technology, currently serving as CEO of AIVIS Inc., leading the company's vision and strategy. With a robust background in electrical engineering from Korea University and a Ph.D. in Computer Vision and Image Processing, Dr. Lee brings extensive expertise to his role. His career includes significant experience as a senior researcher at Suprema Inc., where he developed advanced fingerprint and facial recognition solutions. In 2020, he managed the pioneering project of developing the world's first under-display fingerprint recognition solution, successfully integrated into devices like the Galaxy S10, A50, and A70, marking a milestone in the industry.
Chief Technology Officer
Ming Fan
Ph.D.
Ming Fan is the CTO of AIVIS, overseeing the technical development of the company. He is dedicated to applying AI to solve pathology problems, customizing AI models for various tasks, and ensuring their real-world applicability. With years of experience from his Ph.D. training at Korea University and work at LG Electronics, Dr. Ming Fan leads the technical aspects of AIVIS. His extensive background in computer vision, image processing, and machine learning enables him to innovate and apply AI solutions effectively in pathology.
Chief Medical Officer
Gyuyeong Kim
M.D.
Gyuyeong Kim is the CMO of AIVIS, where he designs products to address the practical problems faced by pathologists. Leveraging his medical experience, he ensures that AIVIS's solutions effectively meet users' needs. Dr. Kim was trained as a pathology resident at Samsung Medical Center and has conducted research in digital pathology, focusing on visual feature representation and evaluation metrics. He actively engages with the pathology community by attending and presenting at conferences, staying informed of the latest trends. This engagement allows him to lead our product development direction with cutting-edge insights and knowledge.
